News

Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances ...
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.
If you ever find yourself staring down this venomous Texas dweller, be careful. Statistics strongly suggest that it's better ...
Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading ...
which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. Get top local Connecticut stories delivered to you every morning with the News Headlines ...
LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the same period. This investor optimism stems from massive demand for the ...
which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. Get top local stories in Southern California delivered to you every morning with NBC LA's ...
which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. The company maintained its fiscal 2025 sales guidance of $58 billion to $61 billion.